DK3505173T3 - Pyrrolo[1,2-f][1,2,4]triaziner som er nyttige til behandling af infektioner med respiratorisk syncitialvirus - Google Patents

Pyrrolo[1,2-f][1,2,4]triaziner som er nyttige til behandling af infektioner med respiratorisk syncitialvirus Download PDF

Info

Publication number
DK3505173T3
DK3505173T3 DK18209267.6T DK18209267T DK3505173T3 DK 3505173 T3 DK3505173 T3 DK 3505173T3 DK 18209267 T DK18209267 T DK 18209267T DK 3505173 T3 DK3505173 T3 DK 3505173T3
Authority
DK
Denmark
Prior art keywords
pyrrolo
treatment
virus infections
respiratory syncitial
syncitial virus
Prior art date
Application number
DK18209267.6T
Other languages
Danish (da)
English (en)
Inventor
Michael O'neil Hanrahan Clarke
Edward Doerffler
Richard L Mackman
Dustin Siegel
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52003049&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3505173(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of DK3505173T3 publication Critical patent/DK3505173T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06Heterocyclic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK18209267.6T 2013-11-11 2014-11-06 Pyrrolo[1,2-f][1,2,4]triaziner som er nyttige til behandling af infektioner med respiratorisk syncitialvirus DK3505173T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361902544P 2013-11-11 2013-11-11
EP14806123.7A EP3068405B1 (en) 2013-11-11 2014-11-06 Pyrrolo [1,2,f][1,2,4]triazines useful for treating respiratory syncitial virus infections

Publications (1)

Publication Number Publication Date
DK3505173T3 true DK3505173T3 (da) 2022-08-22

Family

ID=52003049

Family Applications (2)

Application Number Title Priority Date Filing Date
DK18209267.6T DK3505173T3 (da) 2013-11-11 2014-11-06 Pyrrolo[1,2-f][1,2,4]triaziner som er nyttige til behandling af infektioner med respiratorisk syncitialvirus
DK14806123.7T DK3068405T3 (da) 2013-11-11 2014-11-06 Pyrrolo [1,2,f][1,2,4]triaziner anvendelige til behandling af respiratoriske syncytialvirusinfektioner

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK14806123.7T DK3068405T3 (da) 2013-11-11 2014-11-06 Pyrrolo [1,2,f][1,2,4]triaziner anvendelige til behandling af respiratoriske syncytialvirusinfektioner

Country Status (36)

Country Link
US (5) US9388208B2 (OSRAM)
EP (3) EP3505173B1 (OSRAM)
JP (7) JP6234571B2 (OSRAM)
KR (4) KR102355881B1 (OSRAM)
CN (3) CN110003215B (OSRAM)
AP (1) AP2016009186A0 (OSRAM)
AU (5) AU2014346665A1 (OSRAM)
BR (1) BR112016010261B1 (OSRAM)
CA (1) CA2928674C (OSRAM)
CL (1) CL2016001120A1 (OSRAM)
CR (1) CR20160220A (OSRAM)
CU (1) CU20160065A7 (OSRAM)
CY (1) CY1121948T1 (OSRAM)
DK (2) DK3505173T3 (OSRAM)
DO (1) DOP2016000107A (OSRAM)
EA (2) EA039734B1 (OSRAM)
ES (2) ES2926155T3 (OSRAM)
GT (1) GT201600086A (OSRAM)
HR (2) HRP20191303T1 (OSRAM)
HU (2) HUE059683T2 (OSRAM)
IL (1) IL245324B (OSRAM)
LT (2) LT3505173T (OSRAM)
MD (1) MD4596C1 (OSRAM)
MX (2) MX376186B (OSRAM)
MY (2) MY197933A (OSRAM)
NZ (1) NZ719592A (OSRAM)
PE (1) PE20160670A1 (OSRAM)
PH (1) PH12016500867A1 (OSRAM)
PL (2) PL3068405T3 (OSRAM)
PT (2) PT3505173T (OSRAM)
SG (1) SG11201603427XA (OSRAM)
SI (2) SI3068405T1 (OSRAM)
TR (1) TR201910961T4 (OSRAM)
UA (1) UA119050C2 (OSRAM)
WO (1) WO2015069939A1 (OSRAM)
ZA (1) ZA201603123B (OSRAM)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5767643B2 (ja) 2009-09-21 2015-08-19 ギリード・サイエンシズ・インコーポレーテッド 1’−置換カルバヌクレオシド類似体の調製のためのプロセスおよび中間体
PE20130400A1 (es) 2010-07-22 2013-04-10 Gilead Sciences Inc Metodos y compuestos para tratar infecciones virales por paramyxoviridae
UA119050C2 (uk) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
TWI678369B (zh) * 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並[3,2-d]嘧啶、呋喃並[3,2-d]嘧啶及吡咯並[3,2-d]嘧啶化合物類
US10358458B2 (en) 2014-09-26 2019-07-23 Riboscience Llc 4′-vinyl substituted nucleoside derivatives as inhibitors of respiratory syncytial virus RNA replication
TWI698444B (zh) * 2014-10-29 2020-07-11 美商基利科學股份有限公司 製備核糖苷的方法
CN118286245A (zh) 2014-12-26 2024-07-05 埃莫里大学 N4-羟基胞苷和衍生物及与其相关的抗病毒用途
PT3349758T (pt) 2015-09-16 2022-07-13 Gilead Sciences Inc Métodos para o tratamento de infeções pelo vírus arenaviridae
US10953029B2 (en) 2015-09-23 2021-03-23 Merck Sharp & Dohme Corp. 4′-Substituted nucleoside reverse transcriptase inhibitors and preparations thereof
CN109071467B (zh) 2016-03-09 2023-04-04 艾丽奥斯生物制药有限公司 无环抗病毒药
CN110869028B (zh) 2017-03-14 2023-01-20 吉利德科学公司 治疗猫冠状病毒感染的方法
KR20190141747A (ko) 2017-05-01 2019-12-24 길리애드 사이언시즈, 인코포레이티드 (S)-2-에틸부틸 2-(((S)-(((2R,3S,4R,5R)-5-(4-아미노피롤로[2,1-f] [1,2,4]트리아진-7-일)-5-시아노-3,4-디히드록시테트라히드로푸란-2-일)메톡시)(페녹시) 포스포릴)아미노)프로파노에이트의 결정질 형태
US10675296B2 (en) 2017-07-11 2020-06-09 Gilead Sciences, Inc. Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
EP3684782A1 (en) * 2017-09-18 2020-07-29 Janssen BioPharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN109748921B (zh) * 2017-11-03 2022-03-22 中国科学院上海药物研究所 N-叔丁氧羰基保护的杂环类化合物、其制备方法及其用于制备c-核苷类似物的方法
US11331331B2 (en) 2017-12-07 2022-05-17 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
US11040975B2 (en) 2017-12-08 2021-06-22 Merck Sharp & Dohme Corp. Carbocyclic nucleoside reverse transcriptase inhibitors
CN108787177B (zh) * 2018-08-07 2024-03-15 中南大学 淤浆法制备黄原酸盐的方法及系统
US12234255B2 (en) 2019-05-14 2025-02-25 Regents Of The University Of Michigan Methods for glycosylation
CN118766947A (zh) 2020-01-27 2024-10-15 吉利德科学公司 用于治疗SARS CoV-2感染的方法
TWI775313B (zh) * 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
TWI791193B (zh) * 2020-02-18 2023-02-01 美商基利科學股份有限公司 抗病毒化合物
TWI883391B (zh) * 2020-02-18 2025-05-11 美商基利科學股份有限公司 抗病毒化合物
CA3171648A1 (en) * 2020-02-18 2021-08-26 Gilead Sciences, Inc. Antiviral compounds
CN111187269A (zh) * 2020-02-27 2020-05-22 江苏阿尔法药业有限公司 一种瑞德西韦中间体的合成方法
CN113336758B (zh) * 2020-03-03 2022-08-19 北京桦冠医药科技有限公司 化合物7-碘吡咯并[2,1-f][1,2,4]三嗪-4-胺的一种新合成方法
CN111233870A (zh) * 2020-03-11 2020-06-05 中国科学技术大学 用于快速制备瑞德西韦药物中间体的方法
CA3169340A1 (en) 2020-03-12 2021-09-16 Pavel R. Badalov Methods of preparing 1'-cyano nucleosides
JP7482250B2 (ja) 2020-04-06 2024-05-13 ギリアード サイエンシーズ, インコーポレイテッド 1’-シアノ置換カルバヌクレオシド類似体の吸入製剤
CN112778310B (zh) 2020-04-20 2025-05-30 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
CN113527303B (zh) * 2020-04-21 2022-06-10 浙江工业大学 一种瑞德西韦母核中间体的制备工艺
CN111440176B (zh) * 2020-04-28 2022-04-26 江苏大学 金属配合物促进的瑞德西韦中间体的合成方法
PL4157272T3 (pl) 2020-05-29 2025-10-20 Gilead Sciences, Inc. Remdesiwir do leczenia zakażeń wirusowych
CN111620903A (zh) * 2020-06-17 2020-09-04 安徽贝克联合制药有限公司 C-核苷类似物以及用于合成瑞德西韦合成的含腈c-核苷类化合物的制备方法及其应用
JP2023531524A (ja) 2020-06-24 2023-07-24 ギリアード サイエンシーズ, インコーポレイテッド 1’-シアノヌクレオシド類似体及びその使用
CN111732618A (zh) * 2020-07-03 2020-10-02 镇江巨杰新材料技术研发中心(有限合伙) 瑞德西韦关键片段的合成方法
CN111793101B (zh) * 2020-07-17 2022-09-30 四川大学 C-核苷化合物的合成方法
WO2022029704A1 (en) 2020-08-06 2022-02-10 Richter Gedeon Nyrt. Remdesivir intermediates
CR20230100A (es) 2020-08-24 2023-04-28 Gilead Sciences Inc Compuestos fosfolípidos y usos de los mismos
LT4204421T (lt) 2020-08-27 2024-06-25 Gilead Sciences, Inc. Virusinių infekcijų gydymui skirti junginiai ir būdai
TW202344257A (zh) * 2020-10-16 2023-11-16 美商基利科學股份有限公司 磷脂化合物及其用途
CN113880846B (zh) * 2020-12-31 2022-10-14 山东诚汇双达药业有限公司 一种7-碘吡咯并[2,1-f][1,2,4]三嗪-4-胺的制备方法
PL4323362T3 (pl) 2021-04-16 2025-08-18 Gilead Sciences, Inc. Sposoby wytwarzania karbanukleozydów z zastosowaniem amidów
AU2022328698B2 (en) 2021-08-18 2025-02-20 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
CN118119624A (zh) 2021-08-20 2024-05-31 盐野义制药株式会社 具有病毒增殖抑制作用的核苷衍生物及其前药
US20230295172A1 (en) 2022-03-02 2023-09-21 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
AU2023227862A1 (en) * 2022-03-03 2024-09-26 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
PE20250419A1 (es) * 2022-03-03 2025-02-14 Gilead Sciences Inc Compuestos antivirales y metodos de elaboracion y uso de los mismos
EP4665737A1 (en) 2023-02-16 2025-12-24 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
US20250084088A1 (en) 2023-08-31 2025-03-13 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
US20250090537A1 (en) 2023-08-31 2025-03-20 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
TW202517647A (zh) 2023-09-28 2025-05-01 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3565070A (en) 1969-02-28 1971-02-23 Riker Laboratories Inc Inhalation actuable aerosol dispenser
FR2224175B1 (OSRAM) 1973-04-04 1978-04-14 Isf Spa
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1017153B (it) 1974-07-15 1977-07-20 Isf Spa Apparecchio per inalazioni
SE438261B (sv) 1981-07-08 1985-04-15 Draco Ab Anvendning i dosinhalator av ett perforerat membran
US4805811A (en) 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US4955371A (en) 1989-05-08 1990-09-11 Transtech Scientific, Inc. Disposable inhalation activated, aerosol device for pulmonary medicine
ES2141108T3 (es) 1991-07-02 2000-03-16 Inhale Inc Metodo y dispositivo para proporcionar medicamentos en aerosol.
US5261538A (en) 1992-04-21 1993-11-16 Glaxo Inc. Aerosol testing method
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5388572A (en) 1993-10-26 1995-02-14 Tenax Corporation (A Connecticut Corp.) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5544647A (en) 1994-11-29 1996-08-13 Iep Group, Inc. Metered dose inhalator
US5622163A (en) 1994-11-29 1997-04-22 Iep Group, Inc. Counter for fluid dispensers
US6116234A (en) 1999-02-01 2000-09-12 Iep Pharmaceutical Devices Inc. Metered dose inhaler agitator
DK2251015T3 (da) * 2000-10-18 2013-05-13 Gilead Pharmasset Llc Modificerede nukleotider til behandling af virusinfektioner og abnorm celleproliferation
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
EP1435974A4 (en) 2001-09-28 2006-09-06 Idenix Cayman Ltd METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATITIS C VIRUS USING 4 'MODIFIED NUCLEOSIDES
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
AR046959A1 (es) * 2003-12-18 2006-01-04 Tibotec Pharm Ltd Morfolinilo que contiene bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio
NZ578556A (en) 2007-01-12 2012-04-27 Biocryst Pharm Inc Antiviral nucleoside analogs
US8242085B2 (en) 2007-05-10 2012-08-14 Biocryst Pharmaceuticals, Inc. Tetrahydrofuro [3,4-D] dioxolane compounds for use in the treatment of viral infections and cancer
ATE515861T1 (de) 2007-07-25 2011-07-15 Nokia Siemens Networks Oy Verfahren zur adressierung von ethernetströmen mit strukturierter gpon-gem-port-id
HUE038946T2 (hu) * 2008-04-23 2018-12-28 Gilead Sciences Inc 1'-szubsztituált carba-nukleozid analógok antivirális kezelésre
WO2010002877A2 (en) * 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
JP5767643B2 (ja) * 2009-09-21 2015-08-19 ギリード・サイエンシズ・インコーポレーテッド 1’−置換カルバヌクレオシド類似体の調製のためのプロセスおよび中間体
BR112012006261B1 (pt) * 2009-09-21 2021-12-21 Gilead Sciences, Inc Compostos análogos de 2'-flúor substituído carbanucleosídeo, composto útil para a preparação do mesmo, composição farmacêutica e uso dos compostos análogos de 2'-flúor substituído carbanucleosídeo
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
KR101995598B1 (ko) * 2010-07-19 2019-07-02 길리애드 사이언시즈, 인코포레이티드 부분입체 이성질성으로 순수한 포스포라미데이트 전구약물의 제조 방법
PE20130400A1 (es) * 2010-07-22 2013-04-10 Gilead Sciences Inc Metodos y compuestos para tratar infecciones virales por paramyxoviridae
TW201305185A (zh) 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之2’-氟取代之碳-核苷類似物
SG188223A1 (en) * 2010-09-20 2013-04-30 Gilead Sciences Inc 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
TW201701876A (zh) 2010-12-20 2017-01-16 吉李德科學股份有限公司 治療c型肝炎病毒(hcv)之方法
WO2012142075A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US20130143835A1 (en) * 2011-12-05 2013-06-06 Medivir Ab HCV Polymerase Inhibitors
EP2794627B1 (en) * 2011-12-22 2018-09-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EA201791916A1 (ru) * 2012-03-13 2018-07-31 Джилид Сайэнс, Инк. 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
NZ706985A (en) 2012-10-08 2018-08-31 Centre Nat Rech Scient 2’-chloro nucleoside analogs for hcv infection
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
UA119050C2 (uk) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ

Also Published As

Publication number Publication date
US20150133395A1 (en) 2015-05-14
MY197933A (en) 2023-07-25
CN110003215A (zh) 2019-07-12
EA039734B1 (ru) 2022-03-04
CN110003215B (zh) 2021-12-17
WO2015069939A1 (en) 2015-05-14
ZA201603123B (en) 2019-08-28
NZ719592A (en) 2017-12-22
CA2928674A1 (en) 2015-05-14
US20180016280A1 (en) 2018-01-18
TR201910961T4 (tr) 2019-08-21
MX2020010628A (es) 2020-10-22
MX376186B (es) 2025-03-07
AU2017232039A1 (en) 2017-10-12
CN105899216B (zh) 2019-03-05
US10377761B2 (en) 2019-08-13
US20190055253A1 (en) 2019-02-21
DOP2016000107A (es) 2016-06-15
EA201792639A1 (ru) 2018-09-28
JP2024041986A (ja) 2024-03-27
US9701682B2 (en) 2017-07-11
AU2021201554B2 (en) 2023-02-02
SI3068405T1 (sl) 2019-08-30
ES2926155T3 (es) 2022-10-24
EP3068405B1 (en) 2019-05-01
JP2022088661A (ja) 2022-06-14
SI3505173T1 (sl) 2022-09-30
US10059716B2 (en) 2018-08-28
AP2016009186A0 (en) 2016-04-30
KR101864973B1 (ko) 2018-06-05
CN114085243A (zh) 2022-02-25
HUE059683T2 (hu) 2022-12-28
EP4122932A1 (en) 2023-01-25
JP2018021051A (ja) 2018-02-08
HRP20191303T1 (hr) 2019-10-18
MX2016006066A (es) 2016-08-12
AU2017232039C1 (en) 2019-07-25
LT3068405T (lt) 2019-08-12
EP3068405A1 (en) 2016-09-21
US20170008897A1 (en) 2017-01-12
AU2023202506A1 (en) 2023-05-11
KR102113705B1 (ko) 2020-05-21
JP2018070658A (ja) 2018-05-10
ES2743619T3 (es) 2020-02-20
KR102355881B1 (ko) 2022-01-25
BR112016010261A2 (OSRAM) 2017-08-08
AU2023202506B2 (en) 2025-01-23
AU2021201554A1 (en) 2021-04-01
MD4596C1 (ro) 2019-05-31
JP2020055855A (ja) 2020-04-09
EP3505173B1 (en) 2022-07-06
CU20160065A7 (es) 2016-09-30
KR102243724B1 (ko) 2021-04-23
PL3505173T3 (pl) 2022-10-17
CN114085243B (zh) 2024-04-26
AU2017232039B2 (en) 2019-03-28
PE20160670A1 (es) 2016-07-10
PL3068405T3 (pl) 2019-10-31
AU2019204381B2 (en) 2021-04-01
AU2014346665A1 (en) 2016-05-19
KR20160074011A (ko) 2016-06-27
CN105899216A (zh) 2016-08-24
KR20180059958A (ko) 2018-06-05
LT3505173T (lt) 2022-10-10
AU2019204381A1 (en) 2019-07-11
EP3505173A1 (en) 2019-07-03
UA119050C2 (uk) 2019-04-25
PH12016500867A1 (en) 2016-06-20
CL2016001120A1 (es) 2017-05-05
PT3068405T (pt) 2019-08-05
BR112016010261B1 (pt) 2022-02-08
EA201690978A1 (ru) 2016-09-30
SG11201603427XA (en) 2016-05-30
KR20200057103A (ko) 2020-05-25
IL245324A0 (en) 2016-06-30
GT201600086A (es) 2018-01-17
MD4596B1 (ro) 2018-10-31
US9388208B2 (en) 2016-07-12
IL245324B (en) 2018-08-30
KR20210046833A (ko) 2021-04-28
PT3505173T (pt) 2022-11-18
JP6234571B2 (ja) 2017-11-22
CR20160220A (es) 2016-07-22
JP7054394B2 (ja) 2022-04-13
MY182986A (en) 2021-02-05
EA029712B1 (ru) 2018-05-31
HUE044960T2 (hu) 2019-12-30
JP6393380B2 (ja) 2018-09-19
JP2021046413A (ja) 2021-03-25
US20250236623A1 (en) 2025-07-24
JP7247155B2 (ja) 2023-03-28
DK3068405T3 (da) 2019-07-29
CA2928674C (en) 2018-10-02
MD20160063A2 (ro) 2016-11-30
HRP20220920T1 (hr) 2022-10-28
JP2017502925A (ja) 2017-01-26
CY1121948T1 (el) 2020-10-14

Similar Documents

Publication Publication Date Title
DK3505173T3 (da) Pyrrolo[1,2-f][1,2,4]triaziner som er nyttige til behandling af infektioner med respiratorisk syncitialvirus
DK3404031T3 (da) Thieno[3,2-d]pyrimidinderivater til behandling af virusinfektioner
DK2852391T3 (da) Systemer til behandling af lungeinfektioner
DK3590928T3 (da) Pyrimidinderivater til behandling af virusinfektioner
PL3174870T3 (pl) Tieno[3,2-d]pirymidyny, furo[3,2-d]pirymidyny i pirolo[3,2- d]pirymidyny przydatne do leczenia zakażeń syncytialnym wirusem oddechowym
IL239859A0 (en) History of 2-aminopyrimidine for the treatment of viral infections
IL240765A0 (en) Macrocyclic daza-furanones for the treatment of viral infections
HUE058737T2 (hu) Eljárások arenaviridae vírusok okozta fertõzések kezelésére
PT2935303T (pt) 4'-fluoro-nucleósidos, 4'-fluoro-nucleótidos e seus análogos para o tratamento de hcv
SG11201502522WA (en) 1,2,4-triazine derivatives for the treatment of viral infections.
DK3294532T3 (da) Forbedringer i forbindelse med fremstilling af vindmøllekomponenter
DK2777689T3 (da) Ny farmaceutisk sammensætning til behandling af svampeinfektioner
DK3362453T3 (da) Cykliske etherderivater af pyrazolo[1,5-a]pyrimidin-3-carboxyamid
LT3010496T (lt) Argininas, skirtas panaudoti osteoartrito gydymui ir (arba) prevencijai
DK2941269T3 (da) Terapeutiske vacciner til behandling af herpes simplex-virus type 2-infektioner
TH1501001789A (th) อนุพันธ์ของ 1,2,4-ไตรอะซีน สำหรับการบำบัดของโรคติดเชื้อไวรัส
TH1501001885A (th) อนุพันธ์ไพโรโล [3,2-d] ไพริมิดีนสำหรับการบำบัดของการติดเชื้อไวรัสและโรคอื่นๆ
SG11201605231RA (en) CRYSTAL (1) OF PYRAZINO[2,1-c][1,2,4]TRIAZINE COMPOUND
TH1601000114A (th) อนุพันธ์ไทอีโน [3,2-d] ไพริมิดีน สำหรับการบำบัดการติดเชื้อไวรัส